ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,642Medicare Part D Prescriptions Filled, Including Refills

Rank: 24 out of 331

$520K Total Retail Price of All Prescriptions

Rank: 18 out of 331

479 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
2% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Puerto Rico
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

2% of this provider’s 11,142 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$41 was the average price of a prescription from this provider, compared to $35 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Puerto Rico
SIMVASTATIN 991 896 1 1
LOSARTAN-HYDROCHLOROTHIAZIDE 615 560 2 14
AMLODIPINE BESYLATE 533 460 3 6
OMEPRAZOLE 492 418 4 5
SYNTHROID 408 343 5 11
GABAPENTIN 390 336 6 7
LOSARTAN POTASSIUM 368 311 7 8
TRAMADOL HCL-ACETAMINOPHEN 312 259 8 18
METFORMIN HCL 300 254 9 2
RANITIDINE HCL 287 245 10 4
LEVOTHYROXINE SODIUM 286 268 11 9
SERTRALINE HCL 244 232 12 28
ALENDRONATE SODIUM 236 188 13 17
METOPROLOL SUCCINATE 223 201 14 24
DICLOFENAC POTASSIUM 220 184 15 32
HYDROCHLOROTHIAZIDE 189 148 16 10
GLIMEPIRIDE 158 154 17 21
ENALAPRIL MALEATE 148 142 18 3
PRAVASTATIN SODIUM 136 125 19 20
ZOLPIDEM TARTRATE 133 117 20 22
DIOVAN HCT 131 119 21 103
QUINAPRIL HCL 124 119 22 106
CLOPIDOGREL 123 120 23 39
ATENOLOL 122 121 24 12
LISINOPRIL 110 90 25 13
DONEPEZIL HCL 106 106 26 38
IRBESARTAN 100 83 27 73
NAMENDA 99 99 28 63
AMLODIPINE BESYLATE-BENAZEPRIL 97 97 29 47
ISOSORBIDE MONONITRATE ER 95 95 30 31
RAMIPRIL 94 94 31 52
CLOTRIMAZOLE-BETAMETHASONE 90 69 32 43
CIPROFLOXACIN HCL 90 81 32 36
AZITHROMYCIN 89 70 34 29
METOPROLOL TARTRATE 87 77 35 16
TAMSULOSIN HCL 81 62 36 34
PLAVIX 79 79 37 46
FAMOTIDINE 78 74 38 50
GLYBURIDE 75 75 R 39 56
TRILIPIX 75 74 39 205
DOXAZOSIN MESYLATE 73 73 41 30
LANTUS 71 54 42 40
GLIPIZIDE ER 69 59 43 121
FUROSEMIDE 64 56 44 15
CARVEDILOL 64 64 44 33
VERAPAMIL ER 64 64 44 35
WARFARIN SODIUM 63 62 47 66
CYMBALTA 62 56 48 113
DIOVAN 60 47 49 69
GLIPIZIDE 60 45 49 19
PANTOPRAZOLE SODIUM 58 56 51 41
ATORVASTATIN CALCIUM 56 54 52 26
GLYBURIDE-METFORMIN HCL 56 51 R 52 54
LATANOPROST 53 53 54 112
EVISTA 50 44 55 61
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 11, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.